MDS Congress,
Currently, only around 20% of patients with TP53-mutant #MyelodysplasticSyndromes achieve complete remission with…
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
Overview of attention for article published in Journal of Clinical Oncology, January 2021
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (98th percentile)
-
High Attention Score compared to outputs of the same age and source (96th percentile)
Mentioned by
- news
- 13 news outlets
- 50 X users
- patent
- 3 patents
- 1 Facebook page
- 1 Redditor
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 319 Mendeley